Literature DB >> 15962545

Epidemiology of pericardial effusions at a large academic hospital in South Africa.

H Reuter1, L J Burgess, A F Doubell.   

Abstract

The aim was to establish the prevalence of large pericardial effusions in the Western Cape Province of South Africa, and to determine the incidence of various types of effusions. A total of 233 patients presented with large pericardial effusions. Each patient underwent tests for HIV, sputum smear and culture, blood culture, blood biochemistry and serological testing. Tuberculous pericardial effusions were diagnosed according to pre-determined criteria. Eighty-four patients (36.1%) were found to be HIV positive; 81 of these (96.4 %) had tuberculous pericarditis. More than 65% of the study population was aged between 15 and 39 years. The prevalence of HIV amongst unemployed individuals was 49.0% compared to 30.0% amongst employed individuals. Tuberculous pericarditis was the most common cause of pericardial effusions (69.5%, n=162). It was concluded that tuberculosis (TB) is a leading cause of pericarditis in this province of South Africa. The prevalence of TB confounded by HIV co-infection is steadily increasing, burdening the health-care facilities.

Entities:  

Mesh:

Year:  2005        PMID: 15962545      PMCID: PMC2870262          DOI: 10.1017/s0950268804003577

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  39 in total

1.  Tailoring diagnosis and management of pericardial disease to the epidemiological setting.

Authors:  Faisal F Syed; Mpiko Ntsekhe; Bongani M Mayosi
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

2.  Application of Ultrasonography in the Diagnosis of Infectious Diseases in Resource-Limited Settings.

Authors:  Enrico Brunetti; Tom Heller; Joachim Richter; Daniel Kaminstein; Daniel Youkee; Maria Teresa Giordani; Samuel Goblirsch; Francesca Tamarozzi
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

Review 3.  Tuberculous pericarditis with and without HIV.

Authors:  Mpiko Ntsekhe; Bongani M Mayosi
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

Review 4.  Effusive-constrictive pericarditis.

Authors:  Faisal F Syed; Mpiko Ntsekhe; Bongani M Mayosi; Jae K Oh
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

5.  Echo-guided pericardiocentesis in patients with clinically significant pericardial effusion. Outcomes over a 10-year period.

Authors:  S Akyuz; A Zengin; E Arugaslan; S Yazici; T Onuk; U S Ceylan; B Gungor; U Gurkan; T Kemaloglu Oz; H Kasikcioglu; N Cam
Journal:  Herz       Date:  2014-12-11       Impact factor: 1.443

6.  Molecular detection of invasive aspergillosis in hematologic malignancies.

Authors:  P Badiee; P Kordbacheh; A Alborzi; M Ramzi; E Shakiba
Journal:  Infection       Date:  2008-10-14       Impact factor: 3.553

7.  Short course for focused assessment with sonography for human immunodeficiency virus/tuberculosis: preliminary results in a rural setting in South Africa with high prevalence of human immunodeficiency virus and tuberculosis.

Authors:  Tom Heller; Claudia Wallrauch; Richard J Lessells; Sam Goblirsch; Enrico Brunetti
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

8.  Tuberculous pericarditis presenting as massive haemorrhagic pericardial effusion.

Authors:  Vivien Yan Chi Lee; John Tai Hung Wong; Hon Cheung Fan; Vincent Tok Fai Yeung
Journal:  BMJ Case Rep       Date:  2012-06-28

Review 9.  Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa.

Authors:  Bongani M Mayosi
Journal:  Heart       Date:  2007-10       Impact factor: 5.994

10.  Extrapulmonary mycobacterial infections in a cohort of HIV-positive patients: ultrasound experience from Vicenza, Italy.

Authors:  Maria Teresa Giordani; Enrico Brunetti; Raffaella Binazzi; Paolo Benedetti; Clara Stecca; Sam Goblirsch; Tom Heller
Journal:  Infection       Date:  2012-09-24       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.